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Abstract Identification of patients who are at increased
risk for contralateral breast cancer is essential to determine
which patients should be routinely screened for contralat-
eral breast cancer using MRI. The aim of this study was to
assess the association of age and tumor morphology with
contralateral breast cancer incidence in a large, nationwide
population-based study in the Netherlands. All patients
with breast cancer stage I–III, diagnosed between 1989 and
2009, were selected from the Netherlands Cancer Registry.
The association between contralateral breast cancer risk
with tumor morphology and age was assessed using com-
peting-risk regression according to Fine & Gray. Overall,
194,898 patients were included. In multivariable analyses,
lobular tumors were significantly associated with an in-
creased risk of contralateral breast cancer within 6 months
(cumulative incidence 1.9 %, subdistribution hazard ratio
(SHR) 1.17, 95 % confidence interval (CI) 1.06–1.30
compared with 1.3 % in ductal tumors, p = 0.002). Age
was also associated with an increased risk of contralateral
breast cancer within 6 months (SHR 2.34, 95 % CI
2.08–2.62, p \ 0.002 for patients over the age of 75 as
compared to patients younger than 50 years). The absolute
risk of contralateral breast cancer within 6 months is only
slightly increased in patients with a lobular tumor and older
patients. In our view, this small increased risk does not
justify standard use of preoperative MRI based on tumor
morphology or age alone. We propose a more personalized
strategy in which additional risk factors (family history,
prognosis of primary tumor, and others) may play a role.
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Introduction
Breast cancer incidence rates are increasing [1, 2], and
consequently, an increased number of patients are at risk
for developing contralateral breast cancer [3]. In general,
incidence rates for contralateral breast cancer after primary
breast cancer of approximately 1 % per year have been
reported [4]. Several studies have shown that survival after
contralateral breast cancer is impaired compared to patients
with unilateral breast cancer [3, 5–7]. Therefore, identifi-
cation of patients who are at increased risk for contralateral
breast cancer is essential in order to determine which pa-
tients should be routinely screened for contralateral breast
cancer using magnetic resonance imaging (MRI). Due to
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the high costs, the use of MRI should be limited to the
patients in which the risk of contralateral breast cancer is
the highest.
Currently, the Dutch breast cancer guideline recom-
mends to perform a preoperative MRI in all patients with
invasive lobular breast cancer, unless an unifocal mass is
observed on a mammogram that is properly assessable [8].
Invasive lobular carcinoma is one of the previously de-
scribed risk factors for contralateral breast. Invasive lobular
carcinoma is characterized by a particular single-file
growth pattern, tends to be larger at diagnosis, estrogen
(ER) and progesterone receptor (PR) positive, more likely
to occur in the older patient and less aggressive than their
ductal counterparts [9, 10].
Also, several previous studies have shown that the risk
of contralateral breast cancer within 6 months after the
initial diagnosis increases with age [3], while the risk of
contralateral breast cancer during follow-up is the highest
in younger patients [4, 5]. However, the Dutch breast
cancer guideline states that MRI is not of additional value
in women aged 70 years or older, even though the inci-
dence of breast cancer increases with age [8].
With the increasing health expenditure of recent years
[11], we question if the standard MRI that is currently
performed in patients with a lobular tumor as well as the
omission of MRI in older patients can be justified.
Therefore, we aimed at assessing the association of age
and tumor morphology with contralateral breast cancer
incidence within 6 months after diagnosis in a large, na-
tionwide population-based study in the Netherlands. In
addition, we assessed the association of these factors with
the risk of contralateral breast cancer after 6 months.
Methods
Study population
Patients were selected from the Netherlands Cancer Reg-
istry. After notification by the nationwide Dutch network
and registry of histo- and cytopathology (PALGA) and the
national hospital discharge databank, trained registry per-
sonnel collected data on diagnosis, staging, and treatment
using the registration and coding manual of the Compre-
hensive Cancer Center the Netherlands. Female patients
diagnosed between 1989 and 2009 who received surgery
for their first primary breast cancer stage I–III were
selected from the Dutch Cancer Registry. Based on a
unique patient number, second primary breast cancers were
linked to each individual patient. All second primary can-
cers that occurred in the contralateral breast after the initial
diagnosis were included. Patients with unknown localiza-
tions of the breast cancer were excluded as it could not be
recalled if the second primary tumor was localized in the
contralateral breast (n = 51).
Statistical analysis
The date of the first breast cancer diagnosis was defined as
the date of pathological diagnosis (usually via biopsy). As
it is unlikely that a new contralateral breast cancer occurs
within 6 months after the initial diagnosis, a division was
made according to previous literature [3, 5, 6] into con-
tralateral breast cancer within 6 months and after 6 months
(following the index cancer). We thereby assumed that any
tumor that occurred within 6 months after the initial
diagnosis was in fact a bilateral tumor. If patients presented
with bilateral breast cancer at first diagnosis, they were
included, and follow-up between the initial diagnosis and
the contralateral breast cancer was defined as 0.00001 days
in order to be able to include these patients in the Fine &
Gray analyses.
Differences between patient groups were assessed using
Chi-square tests. Age was divided into \50, 50–64, 65–74
and 75 years and older. Histological grade was defined as
Grade I, Grade II, or Grade III. Morphology was defined as
ductal, lobular, or other. ER and PR-status were registered
by the Netherlands Cancer Registry starting from the year
2005, and defined as negative, positive, or unknown.
Pathological T-stage and N-stage according to the TNM-
classification that was applicable in the year of diagnosis
were used. If pathological stage was missing, clinical stage
was used. T-stage was categorized as stage I, II, III, IV, or
‘‘unknown’’, and N-stage was analyzed as N0, N1, N2, N3,
or unknown.
Since the occurrence of contralateral breast cancer may
be influenced by the risk of competing endpoints (defined
as death without contralateral breast cancer) [12], the cu-
mulative incidences of contralateral breast cancer can be
overestimated when regular analyses such as the Kaplan–
Meier Method or the Cox Regression model are used.
Therefore, all cumulative incidences were estimated by
competing-risks regression according to Fine & Gray to
assess the risk of a contralateral breast cancer while taking
into account the risks of reaching other, competing end-
points [13]. Cumulative incidences were calculated for the
total cohort and stratified according to lobular and ductal
breast cancer and age. Additionally, the differences in cu-
mulative incidence rates between lobular and ductal breast
cancer were further stratified in periods to study changes
over time. Contralateral breast cancer after 6 months was
assessed using the time between 6 months after diagnosis
and occurrence of contralateral breast cancer or end of
follow-up, with death from any cause as competing event.
Patients who had a contralateral breast cancer within
6 months were excluded from these analyses.
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First, we performed univariate competing-risks regres-
sion, in which all variables as described above were
evaluated. Second, all variables were entered in the mul-
tivariable model (full model).
Results
Patient population
Overall, 194,898 patients with breast cancer stage I–III
who received surgical treatment were included (Table 1).
Follow-up was complete until December 31st, 2010. Me-
dian follow-up was 6.2 years (range 0–21.0 years).
Around seventy five percent of the patients in this cohort
were diagnosed with breast cancer of ductal morphology,
lobular morphology was seen in 11 % of the patients and in
14 % the morphology was unknown (Table 1). Twenty six
percent of the patients in this cohort were younger than
50 years of age, 37 % of the patients ranged between 50 and
64 years and 37 % was older than 65 years (Table 1). The
cumulative incidence of contralateral breast cancer within
6 months was 1.4 % (2,829 cases), while the cumulative
incidence of contralateral breast cancer after 6 months was
3.7 % (7,185 cases) at the end of follow-up (Table 2).
Patient and tumor characteristics in relation
to contralateral breast cancer
Patients with high (pathological) T-stage and N-stage were
more likely to be diagnosed with contralateral breast cancer
within 6 months. The incidence of contralateral breast
cancer was lower in ER-receptor negative patients com-
pared to ER-receptor positive patients (Table 2).
The cumulative incidence of contralateral breast cancer
within 6 months was higher with increasing age, while the
incidence of contralateral breast cancer after 6 months was
lower in the older patients (Table 2; Fig. 1). Lobular tu-
mors were more often associated with contralateral breast
cancer within and after 6 months (1.9 % of patients with
lobular morphology developed contralateral breast cancer
within 6 months versus 1.3 % of patients with ductal
morphology (Fig. 2) and 4.1 % of patients with lobular
morphology developed contralateral breast cancer after
6 months versus 3.5 % of patients with ductal morphology
(p \ 0.001, Fig. 3).
The incidence of contralateral breast cancer within
6 months did not change in previous years, but the incidence
of contralateral breast cancer after 6 months decreased from
6.2 % in patients who were diagnosed between 1989 and
1995 to 1.3 % in patients who were diagnosed between 2003
and 2009 (Table 2). In order to assess if this change was
explained by a difference in length of follow-up, we per-
formed additional sensitivity analyses in which we truncated
the follow-up. These analyses showed that indeed, the ob-
served decrease in CBC was mostly explained by a differ-
ence in length of follow-up, as the difference in contralateral
breast cancer at 3 years and 5 years did not significantly
differ between the three time periods (Attachment 1).
Competing risk analyses
In Table 3, we assessed the risk of contralateral breast
cancer while taking the risk of competing endpoints into
account, as these competing endpoints may influence the
Table 1 Characteristics of the population female breast cancer pa-



































* Localization unknown in 51 patients (excluded)
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risk of contralateral breast cancer. In multivariable com-
peting risk analyses, lobular tumors were significantly as-
sociated with an increased risk for contralateral breast
cancer within 6 months (subdistribution hazard ratio (SHR)
1.17, 95 % C.I. 1.06–1.30 compared with ductal tumors,
p = 0.002) and contralateral breast cancer after 6 months
(SHR: 1.19, 95 % C.I. 1.11–1.28 compared with ductal
tumors, p \ 0.001) (Table 3; Fig. 1). Similarly, increasing
age was associated with an increased risk of contralateral
breast cancer within 6 months (SHR 2.34, 95 % C I
2.08–2.62, p \ 0.001 for patients 75 and older compared
with patients younger than 50 years). Again, the risk of
developing contralateral breast cancer after 6 months de-
creased with increasing age (SHR 0.52, 95 % CI
0.48–0.57, p \ 0.001 for patients 75 and older compared
with patients younger than 50 years).
Table 2 Patient characteristics
in relation to unilateral and
contralateral breast cancer
UBC unilateral breast cancer,
CBC contralateral breast cancer.
For all variables: p \ 0.001
Contralateral breast cancer
UBC CBC B 6 months CBC [ 6 months
n = 184,884 (94.9 %) n = 2829 (1.4 %) n = 7,185 (3.7 %)
Age N (%) N (%) N (%)
\50 48,743 (94.7) 506 (1.0) 2,232 (4.3)
50–64 68,716 (94.9) 909 (1.3) 2,750 (3.8)
65–74 39,171 (94.7) 683 (1.6) 1,521 (3.7)
75? 28,254 (95.2) 731 (2.5) 682 (2.3)
Period
1989–1995 51,018 (92.4) 799 (1.4) 3,413 (6.2)
1996–2002 62,211 (94.3) 939 (1.4) 2,824 (4.3)
2003–2009 71,655 (97.2) 1,091 (1.5) 948 (1.3)
Morphology
Ductal 138,801 (95.2) 1,940 (1.3) 5,036 (3.5)
Lobular 20,254 (94.0) 416 (1.9) 890 (4.1)
Unknown 25,829 (93.7) 473 (1.7) 1,259 (4.6)
T-stage
I 103,115 (94.8) 1,377 (1.3) 4,232 (3.9)
II 67,261 (95.1) 1,129 (1.6) 2,343 (3.3)
III 6,664 (93.8) 144 (2.0) 300 (4.2)
IV 5,691 (94.5) 129 (2.2) 200 (3.3)
Unknown 2,153 (93.1) 50 (2.2) 110 (4.7)
Nodal stage
N0 110,043 (94.4) 1,562 (1.3) 4,954 (4.3)
N1 63,009 (95.4) 1,050 (1.6) 2,008 (3.0)
N2 6,449 (97.1) 98 (1.5) 96 (1.4)
N3 3,119 (96.9) 52 (1.6) 48 (1.5)
Unknown 2,264 (93.9) 67 (2.8) 79 (3.3)
Grade
I 24,145 (95.3) 420 (1.7) 751 (3.0)
II 56,071 (95.5) 924 (1.6) 1,686 (2.9)
III 50,143 (95.8) 606 (1.2) 1,588 (3.0)
Unknown 54,525 (93.1) 879 (1.5) 3,160 (5.4)
Estrogen receptor
Positive 21,315 (94.3) 338 (1.5) 951 (4.2)
Negative 3497 (95.1) 42 (1.1) 140 (3.8)
Unknown 160,072 (94.9) 2,449 (1.5) 6,094 (3.6)
Progesterone receptor
Positive 15,800 (94.3) 250 (1.5) 697 (4.2)
Negative 7,962 (94.4) 118 (1.4) 358 (4.2)
Unknown 161,122 (94.9) 2,461 (1.5) 6,130 (3.6)
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Stratified by age, lobular morphology remained sig-
nificantly associated with risk of contralateral breast cancer
within 6 months in patients aged 64 years or younger
(\50 years: SHR 1.37, 95 % C.I. 1.05–1.80, p = 0.02 for
lobular tumors compared with ductal tumors; 50–64 years:
SHR 1.45, 95 % C.I. 1.20–1.74, p \ 0.001 for lobular tu-
mors) (Attachment 2). A similar trend was observed for the
association between morphology and risk of contralateral
breast cancer within 6 months in patients with tumor stages
T1 (SHR 1.36, 95 % C.I. 1.15–1.60, p \ 0.001) and T2
(SHR 1.22, 95 % C.I 1.0–1.44, p = 0.02), while no asso-
ciation between morphology and contralateral breast can-
cer within 6 months was observed in patients with T3 and
T4 tumors. (Attachment 2).
For contralateral breast cancer after 6 months, patients
below the age of 50 showed a significant association for
tumor morphology, in favor of ductal morphology (SHR
1.37, 95 % C.I. 1.20–1.57, p \ 0.001 for lobular tumors
compared to ductal tumors). Furthermore, patients diag-
nosed with pathological T1 and T2 stages harboring lobular
tumor morphology had a significantly higher risk of con-
tralateral breast cancer after 6 months (T1: SHR 1.13,
95 % C.I. 1.02–1.26, p = 0.02; T2: SHR 1.33, 95 % C.I.
1.18–1.50, p \ 0.001), while tumor morphology was not
significantly associated with risk of contralateral breast
cancer after 6 months in patients with tumor stage T3 and
T4 (Attachment 2).
Discussion
This study shows that the incidence of contralateral breast
cancer, both within and after 6 months, is the highest in
patients with lobular tumor morphology, although the ab-
solute risk difference between ductal and lobular tumors is
small. Older patients are more likely to develop a con-
tralateral breast cancer within 6 months, but less likely to
develop a contralateral breast cancer after this time period,
as compared to their younger counterparts.
According to the Dutch guideline, all patients with an
invasive lobular tumor must receive an MRI, unless a
unifocal mass is observed on a mammogram that is
properly assessable [8]. We observed an increased risk of
contralateral breast cancer in lobular tumors in accor-
dance with previous studies [3, 4, 14]. However, the risk
of synchronous contralateral breast cancer was only 1.2
times higher in patients with lobular tumors, while the
absolute risk difference was 0.6 %. Furthermore, in pa-
tients with high tumor stages, lobular morphology was no
longer a prognostic factor for developing contralateral
breast cancer, which is most likely explained by the fact
that these patients are more likely to die from their breast
cancer before they had the chance to develop contralateral
breast cancer. Since the absolute risk difference between
ductal and lobular tumors was small, and MRI is an ex-
pensive imaging technique (one MRI costs approximately
368 euros in the Netherlands (486 USD)) [15], we propose
that the standard MRI that is currently advised in all pa-
tients with invasive lobular tumors seems inappropriate.
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In addition, the Dutch guideline states that MRI is of
limited diagnostic value in patients older than 70 years.
However, we observed a two-fold increased risk of con-
tralateral breast cancer within 6 months for patients aged
75 years and older as compared to patients under the age of
50 independent of tumor morphology, even in competing
risk regression which takes competing mortality into ac-
count. Also, the absolute risk difference between these
patient groups was 1.5 %, which is even larger than the
difference comparing the morphology types. Furthermore,
the increased risk for patients aged 75 years and older was
observed while the guidelines were applied, which could
mean that a group of older patients are in fact underdiag-
nosed, as they did not receive a standard MRI because of
their age. Therefore, the actual risk for contralateral breast
cancer within 6 months after the initial diagnosis might be
even higher in older patients than these data suggest.
Hence, this finding deserves further attention.
Possibly, our findings can be explained by the fact that
elderly patients more often present with a higher tumor
stage [16], and therefore may have an increased risk of
contralateral breast cancer within 6 months as well.
Moreover, the risk of breast cancer increases with age [1,
17], which implies that the risk of a second, contralateral
breast tumor is also higher in older patients. In contrast, the
risk of contralateral breast cancer during follow-up de-
creased with age, in accordance with several previous
studies [3, 5]. This may be explained by the large pro-
portion of competing mortality in older patients.
Older breast cancer patients comprise a vulnerable
group, as high age is associated with comorbidity and
impaired physical function [18, 19]. Consequently, older
patients are treated according to guidelines less often [20],
and breast cancer mortality in older patients is high, even
though the majority of deaths in older breast cancer pa-
tients occurs from competing events [21]. Moreover, breast
cancer survival of older patients has not improved in recent
years, while the survival of younger patients has sig-
nificantly improved [22], thereby increasing the survival
gap between old and young breast cancer patients. Possi-
bly, the increased incidence of contralateral breast cancer
in this older population could explain part of the survival
difference between young and older patients, as contralat-
eral breast cancer is associated with decreased breast can-
cer survival [3, 5].
This leads to the question: should we routinely screen
older patients for clinically and radiologically occult con-
tralateral breast cancer? One could argue that as we have
shown that older breast cancer patients are at increased risk
of developing contralateral breast cancer within 6 months,
it might be an option to screen for contralateral breast
cancer in all older breast cancer patients. On the other
hand, this can be time-consuming and expensive, espe-
cially if techniques such as MRI are used, and the ‘‘number
needed to MRI’’ is still rather high. Especially in older
patients with multiple comorbidities, the added value of
preoperative screening for contralateral breast cancer might
be small, as the remaining life expectancy may be smaller
than the time to development of contralateral breast cancer
or breast cancer death. Also, mammography may be suf-
ficient for preoperative screening in older patients, as breast
density decreases with age. Hence, future studies should
investigate the value and cost-effectiveness of preoperative
MRI in older breast cancer patients. We propose that
Table 3 Association (competing risk regression with death as competing risk) between morphology and age with CBC
CBC B 6 months
Multivariable analyses






















Ductal 1,940 (1.3) 2,854 (2.0) 1.0 (reference) 0.002 5,036 (3.6) 40,867 (29.5) 1.0 (reference) \0.001
Lobular 416 (1.9) 394 (1.8) 1.17 (1.06–1.30) 890 (4.4) 6,355 (31.2) 1.19 (1.11–1.28)
Age
\50 506 (1.0) 409 (7.9) 1.0 (reference) \0.001 2,232 (4.3) 10,448 (20.3) 1.0 (reference) \0.001
50–64 909 (1.3) 679 (9.4) 1.29 (1.16–1.44) 2,750 (3.8) 15,205 (21.0) 0.91 (0.86–0.97)
65–74 683 (1.6) 812 (16.5) 1.68 (1.50–1.89) 1,521 (3.7) 14,457 (34.9) 0.82 (0.77–0.88)
C75 731 (2.5) 2,027 (68.3) 2.34 (2.08–2.62) 682 (2.3) 18,577 (62.6) 0.52 (0.48–0.57)
Adjusted for grade, period, T-stage and nodal stage
* Mortality within 6 months
** T0 for follow-up after 6 months, exclusion of patients with CBC B 6 months
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preoperative MRI should be used on a more personalized
basis based on tumor characteristics, remaining life ex-
pectancy, and patient’s preferences.
Strengths and weaknesses
The main strength of this study was the use of a large
population-based database that was derived from the
Netherlands Cancer Registry, as it comprises well-registered
data of a large number of patients. Furthermore, to our
knowledge this study is the first one that used competing risk
analyses according to Fine and Gray, which is a major
strength of the analyses as we have shown that competing
risk plays an important role when investigating risk factors
for contralateral breast cancer, especially in older patients.
Previous studies that investigated risk factors for contralat-
eral breast cancer generally used Cox proportional hazard
models. However, several factors which can be associated
with contralateral breast cancer, such as high disease stage
[3] and high age, can also lead to a high mortality and
therefore to a large proportion of competing events. There-
fore, we propose that analyses investigating risk factors for
contralateral breast cancer, should always be performed in
analyses that take these competing events into account.
Of course, this study is also to some extend limited.
Importantly, we depended on the reports of individual
pathologists to determine if a tumor was classified as
contralateral breast cancer or recurrence. Only tumors that
were classified as contralateral breast cancer by the
pathologist were registered by the Cancer Registry as such,
which may lead to heterogeneity in the definition of con-
tralateral breast cancer. Also, the Netherlands Cancer
Registry does not register comorbid diseases, therefore we
could not adjust for this in multivariable competing risk
analyses. Furthermore, the absence of detailed data on
adjuvant treatment limits the analyses. Improvements in
adjuvant therapy may partly explain the observed decrease
in contralateral breast cancer in most recent years, although
this may also be explained by the limited length of follow-
up. Finally, it must be kept in mind that the incidence rates
of contralateral breast cancer were (mostly) observed in an
era were the guidelines were applied, which means that
they may have influenced the observed incidence rates. The
first multidisciplinary guideline from 2002 stated that
‘‘regular follow-up using mammography’’ should be per-
formed in patients with lobular carcinoma [23]. The 2008
guideline that is currently used advices pre-operative MRI
[8], and it is likely that this method has been gradually
adopted between 2002 and 2008. However, if this would
have affected the observed incidence rates, it would have
resulted in an increase of contralateral breast cancer. Since
we did not observe this increase, it is unlikely that it has
strongly influenced our analyses.
In conclusion, the absolute risk of contralateral breast
cancer within 6 months is low in patients with ductal as
well as lobular breast cancer, although patients with lobular
tumors were at a slightly increased risk of contralateral
breast cancer. Furthermore, increasing age was associated
with a high risk of contralateral breast cancer within
6 months, while the risk of contralateral breast cancer after
6 months decreased with increasing age. We propose that
the current guidelines should not advice to perform a
standard MRI in all patients with lobular breast cancer, as
the benefits do probably not outweigh the costs. Instead,
preoperative MRI should be used on a more personalized
basis based on tumor characteristics, remaining life ex-
pectancy, and patient’s preferences.
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